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Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently 
from the basolateral surface expected to be encountered during intravenous delivery to 
treat disseminated cancer 
ABSTRACT 
Enadenotucirev (EnAd) is a group B oncolytic adenovirus developed for systemic delivery 
and currently undergoing clinical evaluation for advanced cancer therapy. For differentiated 
carcinomas, systemic delivery would likely expose virus particles to the basolateral surface of 
cancer cells rather than the apical surface encountered during natural infection. Here, we 
compare the ability of EnAd and adenovirus type-5 (Ad5) to infect polarised colorectal 
carcinoma cells from the apical or basolateral surfaces. Whereas Ad5 infection was more 
efficient via the apical than basolateral surface, EnAd readily infected cells from either 
surface. Progeny particles from EnAd were released preferentially via the apical surface for 
all cell lines and routes of infection. These data further support the utility of group B 
adenoviruses for systemic delivery and suggest that progeny virus are more likely to be 
released into the tumour rather than back through the basolateral surface into the blood 
stream. 
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